The Palmieri Report previously reported on the FDA investigating reports of myocarditis from the Moderna vax.
FDA Investigating Reports Of Myocarditis Risk From Moderna Vaccine
This has hurt Moderna.
Their stock dropped after the decision.
Shares in Moderna Inc. dropped at least 5% as trading opened Monday after a delay in the decision to approve the COVID-19 vaccine for adolescents ages 12-17.
The U.S. Food and Drug Administration (FDA) on Friday notified Moderna that the agency would require additional time to review and evaluate possible risks associated with the vaccine – particularly, a possible risk of myocarditis after vaccination.
The FDA delay could last several weeks, but the timing is unclear. The agency merely plans to further review data before making a final decision.
However, that delay alone was enough to spook some investors into dumping their Moderna shares. The stock dropped 5% after trading started Monday morning. As of 10 a.m., the stock price had gone up and down again, and the value was down by about 6%.
The Palmieri Report is a Pro-America News Outlet founded by Jacob Palmieri. The Palmieri Report is dedicated to giving people the truth so that they can form their own informed political opinions. You can help us beat Big Tech by following us on GETTR , Telegram, and Rumble.
